Assembly Biosciences Stock News

Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts Read more

Zacks Investment Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. The firm currently has $2.50 price objective on the biopharmaceutical companys stock. According to Zacks, Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for [] Read more

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti Read more

Brokerages expect Assembly Biosciences, Inc. (NASDAQ:ASMB) to announce earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Assembly Biosciences earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.57). Assembly Biosciences reported earnings of ($1.11) per share in the same quarter last year, which [] Read more

Assembly Biosciences, Inc. (NASDAQ:ASMB) has earned a consensus recommendation of Hold from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have [] Read more

Renaissance Technologies LLC lowered its stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 38.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 355,841 shares of the biopharmaceutical companys stock after selling 221,494 shares during the period. Renaissance Technologies LLC owned 0.79% [] Read more

Bridgeway Capital Management LLC trimmed its position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 57.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 64,000 shares of the biopharmaceutical companys stock after selling 86,000 shares during the period. Bridgeway Capital Management LLCs holdings in Assembly Biosciences were worth $248,000 as of its [] Read more

Assembly Biosciences (NASDAQ:ASMB) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts consensus estimates of ($0.57) by $0.16, MarketWatch Earnings reports. ASMB stock traded down $0.06 during mid-day trading on Friday, hitting $3.11. The stock had a trading volume of 383,414 shares, compared to its average [] Read more

Read more

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the third quarter ended September 30, 2021. Read more

Assembly Biosciences (NASDAQ:ASMB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assemblys [] Read more

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking Read more

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core inhibitor data will be highlighted in one oral and two poster presentations, Read more

SG3 Management LLC bought a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the biopharmaceutical companys stock, valued at approximately $39,000. Several other hedge funds and other institutional investors also recently modified their [] Read more

Read more